These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

771 related items for PubMed ID: 9171934

  • 21. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S, Richter G, Noffz G, Dörken B, Blankenstein T.
    J Immunol; 1997 Mar 15; 158(6):2834-41. PubMed ID: 9058819
    [Abstract] [Full Text] [Related]

  • 22. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK.
    J Immunol; 2009 Apr 01; 182(7):4217-25. PubMed ID: 19299720
    [Abstract] [Full Text] [Related]

  • 23. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.
    Cancer Res; 2005 Feb 01; 65(3):1063-70. PubMed ID: 15705908
    [Abstract] [Full Text] [Related]

  • 24. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1995 May 01; 25(5):1154-62. PubMed ID: 7539748
    [Abstract] [Full Text] [Related]

  • 25. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
    Guo C, Liu QG, Yang W, Yao YM.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb 01; 28(2):188-92. PubMed ID: 18250039
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity.
    Nakazaki Y, Tani K, Lin ZT, Sumimoto H, Hibino H, Tanabe T, Wu MS, Izawa K, Hase H, Takahashi S, Tojo A, Azuma M, Hamada H, Mori S, Asano S.
    Gene Ther; 1998 Oct 01; 5(10):1355-62. PubMed ID: 9930341
    [Abstract] [Full Text] [Related]

  • 29. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
    Kim SH, Carew JF, Kooby DA, Shields J, Entwisle C, Patel S, Shah JP, Fong Y.
    Cancer Gene Ther; 2000 Sep 01; 7(9):1279-85. PubMed ID: 11023201
    [Abstract] [Full Text] [Related]

  • 30. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Kuzushita N, Ito A, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Hepatology; 1999 Aug 01; 30(2):422-9. PubMed ID: 10421650
    [Abstract] [Full Text] [Related]

  • 31. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dörken B, Blankenstein T.
    Eur J Immunol; 1997 Jul 01; 27(7):1657-62. PubMed ID: 9247574
    [Abstract] [Full Text] [Related]

  • 36. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J, Nakamoto T, Kasaoka Y, Usui T, Hamada H.
    Hiroshima J Med Sci; 2000 Mar 01; 49(1):73-82. PubMed ID: 10824460
    [Abstract] [Full Text] [Related]

  • 37. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines.
    Stoppacciaro A, Paglia P, Lombardi L, Parmiani G, Baroni C, Colombo MP.
    Eur J Immunol; 1997 Sep 01; 27(9):2375-82. PubMed ID: 9341783
    [Abstract] [Full Text] [Related]

  • 38. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
    Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE.
    J Immunol; 1997 Jul 15; 159(2):664-73. PubMed ID: 9218581
    [Abstract] [Full Text] [Related]

  • 39. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G, Hoffmann P, Pouwels M, Zlotta A, Schulman C, Velu T, Bruyns CA.
    J Immunother; 2009 Jul 15; 32(2):140-4. PubMed ID: 19238012
    [Abstract] [Full Text] [Related]

  • 40. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE.
    Cancer Res; 2003 May 15; 63(10):2546-52. PubMed ID: 12750278
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.